BioCentury | Feb 28, 2020
Deals

Biogen expands its modality toolkit in Alzheimer’s and Parkinson’s with Sangamo deal

In its latest CNS partnership, Biogen is doubling down on targets already in its pipeline with a gene regulation technology from Sangamo it hopes will shut down target expression altogether. By closing off target expression,...
BioCentury | Feb 27, 2020
Product Development

Neurimmune launches CV trial, first clinical antibody program outside the brain

As the first antibody out of Neurimmune’s reverse translation platform -- aducanumab -- heads for FDA submission this year, the biotech is looking beyond its core focus in CNS diseases. On Thursday, Neurimmune AG said...
BioCentury | Jun 22, 2019
Product Development

Is tau the new amyloid?

After finally getting the message that they need to look beyond amyloid to treat Alzheimer’s disease, pharmas are lining up behind tau as the next big target. The question is whether they can pick out...
BioCentury | Oct 28, 2017
Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
Items per page:
1 - 4 of 4